No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
SLS250117P3000
- 0.00
- 0.000.00%
15min DelayClose Dec 24 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest3.00Strike Price0.00Turnover0.00%IV-222.93%PremiumJan 17, 2025Expiry Date2.07Intrinsic Value100Multiplier23DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.54Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Promising Phase 2 Results and Strategic Potential Drive Buy Rating for SELLAS Life Sciences' SLS009
Express News | Sellas Life Sciences Group: Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating Interim Analysis
Express News | Sellas Life Sciences Group: Regal Independent Data Monitoring Committee to Perform Interim Analysis in Jan 2025
Express News | Sellas Life Sciences Triggers Interim Analysis in Phase 3 Regal Trial of Gps in Acute Myeloid Leukemia
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
SELLAS Reports Positive Survival Data From Mid-stage Trial of Its Leukemia Treatment